Plain-English translation of NCT06857773 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Neoplasms research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a combination approach works better than standard treatment alone for people with colorectal cancer that has spread to the liver. Some participants will receive standard chemotherapy, while others will undergo surgery to have a special pump placed that delivers Floxuridine directly to the liver, combined with standard chemotherapy. The goal is to see if this targeted medication delivery approach can help more patients become candidates for surgery and improve their survival.
Currently, many people with colorectal cancer spread to the liver cannot have surgery to remove it. Researchers believe that delivering medication directly to the liver tumors through a pump might work better than just using standard chemotherapy alone, potentially allowing more patients to eventually have surgery and improve their outcomes.
You likely qualify if…
You likely don't qualify if…
If you are in the standard treatment group, you will receive chemotherapy on a regular schedule. If you are in the experimental group, you will first have surgery to place the pump and remove your primary tumor, then receive the medication through the pump (cycling every 4 weeks) along with standard chemotherapy (cycling every 2 weeks). Both groups will have imaging scans before and after treatment, and doctors will evaluate whether your liver tumors can be removed surgically. You will also complete quality-of-life questionnaires throughout the trial.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Netherlands